Plant Name: Orostachys japonicus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CTDSP1; ALPI; RECQL; ALPL; TDP1; HPGD; PGD; HSD17B1; AKR1B1; HSD17B2; GFER; HSD17B10; NOX4; ALDH1A1; ALOX15; APEX1; POLB; | |
| GAA; | |
| BCL2; | |
| DAPK1; MET; FLT3; MAPK14; EGFR; FYN; | |
| CA2; CA1; CA12; CA9; CA5B; CA3; CA14; CA7; CA5A; CA4; CA6; | |
| AR; | |
| ESRRA; | |
| ALOX5; TYR; XDH; | |
| KDM4E; | |
| BACE1; | |
| HIF1A; TP53; NFKB1; AHR; | |
| FUT7; | |
| ABCG2; ABCC1; | |
| SLCO1B3; SLCO1B1; | |
| LMNA; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
| Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | PGD | 6-phosphogluconate dehydrogenase | P52209 | CHEMBL3404 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Miscellaneous ion channel | BCL2 | Apoptosis regulator Bcl-2 | P10415 | CHEMBL4860 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
| SLC superfamily of solute carriers | SLCO1B3 | Solute carrier organic anion transporter family member 1B3 | Q9NPD5 | CHEMBL1743121 |
| SLC superfamily of solute carriers | SLCO1B1 | Solute carrier organic anion transporter family member 1B1 | Q9Y6L6 | CHEMBL1697668 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.568E-11 | 6.062E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.382E-09 | 3.181E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.644E-09 | 3.262E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.881E-08 | 1.651E-05 | ALOX15, ALOX5, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, XDH |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 9.268E-08 | 4.485E-05 | ABCC1, CA2, CA4, CA9, EGFR, HPGD, SLCO1B1, SLCO1B3 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.116E-07 | 5.019E-05 | ALPI, AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.193E-07 | 1.220E-04 | EGFR, MAPK14, MAPT, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:2001300; lipoxin metabolic process | 5.379E-07 | 1.889E-04 | ALOX15, ALOX5, HPGD |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.379E-07 | 1.889E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0070988; demethylation | 9.867E-07 | 3.160E-04 | APEX1, CYP1A1, CYP1A2, CYP2C9, KDM4E |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.101E-06 | 3.424E-04 | ALPL, APEX1, AR, CYP1A1, CYP1B1, EGFR, FLT3, NFKB1, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.544E-06 | 6.924E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.085E-25 | 2.363E-21 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 5.097E-06 | 1.337E-03 | ALPL, CYP1A1, EGFR, TP53, TYR |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.840E-06 | 1.462E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 9.172E-06 | 2.148E-03 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:2000045; regulation of G1/S transition of mitotic cell cycle | 9.897E-06 | 2.293E-03 | APEX1, BCL2, CTDSP1, CYP1A1, EGFR, TP53 |
| BP | GO:0032501; multicellular organismal process | GO:0048546; digestive tract morphogenesis | 1.474E-05 | 3.206E-03 | BCL2, EGFR, HIF1A |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.474E-05 | 3.206E-03 | ALOX15, ALOX5, HPGD |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.557E-05 | 3.292E-03 | AR, BCL2, DAPK1, FYN, LMNA |
| BP | GO:0050896; response to stimulus | GO:0034614; cellular response to reactive oxygen species | 1.960E-05 | 4.065E-03 | AKR1B1, APEX1, CYP1B1, EGFR, TP53 |
| BP | GO:0008283; cell proliferation | GO:0042127; regulation of cell proliferation | 2.169E-05 | 4.415E-03 | AHR, AKR1B1, AR, BCL2, CYP1B1, EGFR, ESRRA, FLT3, FYN, HIF1A, HPGD, LMNA, MAPK14, NOX4, TP53, XDH |
| BP | GO:0050896; response to stimulus | GO:0010332; response to gamma radiation | 2.215E-05 | 4.466E-03 | BCL2, NOX4, POLB, TP53 |
| BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 2.340E-05 | 4.674E-03 | AR, BCL2, CA2, CA9, EGFR, HIF1A, MET |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.746E-05 | 5.196E-03 | CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 2.768E-05 | 5.196E-03 | CA3, FYN, HPGD, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 2.963E-05 | 5.468E-03 | ABCC1, AKR1B1, ALDH1A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, EGFR |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 3.259E-05 | 5.963E-03 | AKR1B1, APEX1, CYP1B1, NFKB1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 3.462E-05 | 6.179E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:1901615; organic hydroxy compound metabolic process | 3.547E-05 | 6.279E-03 | AKR1B1, ALDH1A1, ALOX15, BCL2, CYP1A1, CYP1B1, HIF1A, TYR |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 4.590E-05 | 7.515E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0007569; cell aging | 4.625E-05 | 7.515E-03 | BCL2, MAPK14, NOX4, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.590E-05 | 7.515E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0008210; estrogen metabolic process | 5.234E-05 | 8.380E-03 | CYP1B1, HSD17B1, HSD17B2 |
| BP | GO:0050896; response to stimulus | GO:0048545; response to steroid hormone | 5.414E-05 | 8.465E-03 | ALPL, AR, BCL2, CA2, EGFR, FLT3 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 5.482E-05 | 8.465E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.482E-05 | 8.465E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0005497; androgen binding | 5.482E-05 | 8.465E-03 | ALDH1A1, AR |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.706E-19 | 4.141E-15 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 7.565E-18 | 3.534E-14 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0055114; oxidation-reduction process | 6.517E-15 | 1.774E-11 | AKR1B1, ALDH1A1, ALOX15, ALOX5, APEX1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, GAA, GFER, HPGD, HSD17B1, HSD17B10, HSD17B2, KDM4E, MAPK14, NOX4, PGD, TYR, XDH |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.681E-25 | 1.009E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 9.091E-09 | 6.864E-07 | GAA; ALOX15; AKR1B1; CYP2C19; PGD; TYR; HSD17B10; CYP2C9; FUT7; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPL; ALPI; XDH |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.596E-07 | 1.810E-05 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 2.285E-06 | 4.312E-05 | AR; FLT3; DAPK1; BCL2; HIF1A; MET; TP53; EGFR; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.638E-07 | 2.884E-05 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.430E-06 | 3.403E-05 | ABCC1; BCL2; FYN; MAPK14; TP53; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.578E-06 | 3.403E-05 | FLT3; TP53; MET; HIF1A; EGFR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 6.453E-06 | 9.745E-05 | AR; BCL2; TP53; EGFR; NFKB1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.535E-06 | 3.403E-05 | CYP2C9; CYP1A2; ALOX15; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.309E-06 | 7.230E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP2C19 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 2.614E-05 | 3.589E-04 | ABCC1; BCL2; CYP1B1; TP53; MET; EGFR; NFKB1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.353E-05 | 4.219E-04 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 4.831E-05 | 5.211E-04 | MAPK14; MET; EGFR; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 4.043E-05 | 4.696E-04 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.386E-05 | 6.027E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.726E-05 | 5.764E-04 | SLCO1B1; CA2; SLCO1B3; ABCG2 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.290E-04 | 2.196E-03 | MAPK14; TP53; HIF1A; MET; EGFR |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.887E-04 | 1.583E-03 | HPGD; FLT3; TP53; MET; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.429E-04 | 1.747E-03 | BCL2; HIF1A; EGFR; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.346E-04 | 2.196E-03 | CYP2C9; ALOX5; ALOX15; CYP2C19 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.080E-04 | 2.567E-03 | ALOX5; BCL2; MAPK14; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.348E-04 | 2.626E-03 | BCL2; MAPK14; TP53; NFKB1 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 7.767E-04 | 4.044E-03 | LMNA; BCL2; TP53; NFKB1 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 9.253E-04 | 4.657E-03 | MAPT; MAPK14; TP53; EGFR; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 6.409E-04 | 3.584E-03 | MAPK14; TP53; EGFR; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 2.229E-04 | 1.747E-03 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.400E-04 | 1.747E-03 | DAPK1; TP53; EGFR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 9.778E-04 | 4.763E-03 | TP53; EGFR; NFKB1 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 3.298E-03 | 1.250E-02 | BCL2; TP53; MET; EGFR; NFKB1 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.980E-03 | 1.184E-02 | BCL2; MAPK14; TP53; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.980E-03 | 1.184E-02 | BCL2; FYN; MET; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.209E-03 | 5.531E-03 | TP53; MET; EGFR |
| hsa05014 | Amyotrophic lateral sclerosis (ALS)_Homo sapiens_hsa05014 | 4.592E-04 | 2.667E-03 | BCL2; MAPK14; TP53 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 3.311E-03 | 1.250E-02 | BCL2; MAPK14; NFKB1 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.113E-03 | 5.250E-03 | CYP2C9; CYP1A2; CYP2C19 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.362E-03 | 6.050E-03 | FYN; MET; EGFR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 2.098E-03 | 8.798E-03 | BCL2; TP53; NFKB1 |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.595E-03 | 1.292E-02 | FYN; MAPK14; NFKB1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.978E-03 | 2.395E-02 | FYN; MAPK14; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 9.193E-03 | 2.953E-02 | BCL2; TP53; NFKB1 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 7.574E-03 | 2.486E-02 | FYN; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.342E-02 | 3.897E-02 | BACE1; MAPT; HSD17B10 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.565E-02 | 4.260E-02 | BCL2; MAPK14; NFKB1 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.190E-02 | 3.643E-02 | TP53; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.580E-02 | 4.260E-02 | TP53; EGFR |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.720E-02 | 4.479E-02 | FYN; MAPK14 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 1.032E-02 | 3.247E-02 | TP53; EGFR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.231E-02 | 3.643E-02 | FLT3; NFKB1 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.916E-02 | 4.789E-02 | MAPK14; NFKB1 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.444E-02 | 4.115E-02 | BCL2; TP53 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.966E-02 | 4.789E-02 | TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.626E-02 | 4.308E-02 | MET; HIF1A |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.966E-02 | 4.789E-02 | MAPK14; NFKB1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 1.231E-02 | 3.643E-02 | MAPK14; NFKB1 |
| hsa04622 | RIG-I-like receptor signaling pathway_Homo sapiens_hsa04622 | 1.817E-02 | 4.650E-02 | MAPK14; NFKB1 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.068E-02 | 4.958E-02 | MAPK14; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 1.580E-02 | 4.260E-02 | MAPK14; NFKB1 |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 7.475E-03 | 2.486E-02 | ABCC1; ABCG2 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 3.529E-03 | 1.292E-02 | GAA; AKR1B1 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 4.259E-03 | 1.496E-02 | POLB; APEX1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 2.080E-03 | 8.798E-03 | CA2; CA4 |
| hsa00790 | Folate biosynthesis_Homo sapiens_hsa00790 | 7.610E-04 | 4.044E-03 | ALPL; ALPI |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 8.507E-05 | 7.556E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; EGFR; EGFR; EGFR; AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | BCL2; HIF1A; CA9; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ALOX5; ALOX5; ESRRA |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ALOX5; MAPK14; ABCC1; ESRRA |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MET; FLT3; CA9; EGFR |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
| C00-D49: Neoplasms | Cancer | C00-C96 | BCL2; BCL2; AR; HIF1A; TP53; MET; CA1; FLT3; FLT3; CA9; MAPK14; NFKB1; EGFR |
| NA: NA | Rheumatold arthritis | NA | MAPK14 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR |
| C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| C00-D49: Neoplasms | Bladder cancer | C67 | AR; EGFR |
| I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; MAPK14 |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA |
| NA: NA | HIV infections | NA | AHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR; ESRRA |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Amyotrophic lateral sclerosis | G12.2 | BCL2 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ALOX5; TYR; MAPK14; AKR1B1; ESRRA |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
| NA: NA | Male hypogonadism | NA | AR |
| C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| C00-D49: Neoplasms | AML | NA | FLT3 |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | BCL2; AHR |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| NA: NA | Acute respiratory distress syndrome | NA | MAPK14 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; FLT3; EGFR; EGFR |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; ALPL |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
| H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| C00-D49: Neoplasms | Advanced melanoma | C43 | BCL2 |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53; FLT3; FLT3 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; EGFR; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Breast cancer | C50 | BCL2; AR; FLT3; FLT3; CA9; EGFR; EGFR; EGFR |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | BCL2; EGFR |
| C00-D49: Neoplasms | Prostate cancer | C61 | BCL2; AR; AR; FLT3; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | BCL2; ALOX5; FLT3; MAPK14; EGFR |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1; ABCC1; ABCC1 |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5; ESRRA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| NA: NA | Inflammatory diseases | NA | MAPK14 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | ALOX5; MAPK14 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; EGFR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ALOX5; MAPK14 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR |
| N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
| C00-D49: Neoplasms | Leukemia | C90-C95 | BCL2; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA |